AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Price Performance

ABBV Stock traded down $0.10 during mid-day trading on Monday, reaching $142.50. 11,655 shares of the company's stock were exchanged, compared to its average volume of 7,178,582. The company has a market cap of $251.95 billion, a price-to-earnings ratio of 20.20, a price-to-earnings-growth ratio of 4.00 and a beta of 0.70. The stock's 50 day moving average is $146.89 and its 200 day moving average is $150.56. The company has a debt-to-equity ratio of 4.15, a current ratio of 0.84 and a quick ratio of 0.75. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91.

AbbVie (NYSE:ABBV - Get Rating) last issued its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The company had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. AbbVie's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.11 earnings per share. On average, research analysts expect that AbbVie will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be given a $1.41 dividend. The ex-dividend date is Thursday, July 14th. This represents a $5.64 annualized dividend and a dividend yield of 3.96%. AbbVie's dividend payout ratio (DPR) is presently 79.89%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ABBV shares. Wells Fargo & Company raised their price objective on AbbVie from $165.00 to $200.00 in a research report on Monday, May 2nd. BMO Capital Markets boosted their price target on AbbVie from $161.00 to $174.00 and gave the stock an "outperform" rating in a report on Monday, April 25th. Piper Sandler reduced their price objective on AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Atlantic Securities cut their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating on the stock in a research report on Monday, August 1st. Finally, SVB Leerink initiated coverage on AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and a consensus target price of $159.63.

Insider Activity

In other news, Vice Chairman Michael Severino sold 79,801 shares of the firm's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total value of $12,041,970.90. Following the transaction, the insider now owns 152,103 shares in the company, valued at $22,952,342.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.08% of the company's stock.